Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID),BMJ Open Respiratory Research

当前位置： X-MOL 学术 › BMJ Open Respir. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
BMJ Open Respiratory Research ( IF 4.1 ) Pub Date : 2021-09-01 , DOI: 10.1136/bmjresp-2021-001049
Jim M Wild ₁ , Joanna C Porter _{2,

3,

4} , Philip L Molyneaux _{5,

6} , Peter M George _{5,

6} , Iain Stewart ₅ , Richard James Allen ₇ , Raminder Aul ₈ , John Kenneth Baillie ₉ , Shaney L Barratt ₁₀ , Paul Beirne ₁₁ , Stephen M Bianchi ₁₂ , John F Blaikley _{13,

14} , Jonathan Brooke _{15,

16,

17} , Nazia Chaudhuri _{14,

18} , Guilhem Collier ₁ , Emma K Denneny _{2,

3,

4} , Annemarie Docherty ₁₉ , Laura Fabbri ₅ , Michael A Gibbons _{20,

21} , Fergus V Gleeson ₂₂ , Bibek Gooptu _{23,

24} , Ian P Hall _{16,

17} , Neil A Hanley _{14,

25} , Melissa Heightman ₃ , Toby E Hillman ₃ , Simon R Johnson _{16,

17} , Mark G Jones _{26,

27} , Fasihul Khan _{16,

17} , Rod Lawson ₁₂ , Puja Mehta _{2,

28} , Jane A Mitchell ₅ , Manuela Platé _{2,

29} , Krisnah Poinasamy ₃₀ , Jennifer K Quint ₅ , Pilar Rivera-Ortega ₁₈ , Malcolm Semple ₃₁ , A John Simpson _{32,

33} , Djf Smith _{5,

6} , Mark Spears _{34,

35} , LIsa G Spencer ₃₆ , Stefan C Stanel _{18,

37} , David R Thickett _{38,

39} , A A Roger Thompson ₁ , Simon Lf Walsh ₅ , Nicholas D Weatherley ₁ , Mark Everard Weeks ₅ , Dan G Wootton _{36,

40} , Chris E Brightling ₂₄ , Rachel C Chambers ₂ , Ling-Pei Ho _{41,

42} , Joseph Jacob _{4,

43} , Karen Piper Hanley ₃₇ , Louise V Wain _{7,

24} , R Gisli Jenkins _{6,

44}

Affiliation

Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, UK.
Centre for Inflammation and Tissue Repair, UCL Respiratory, University College London, London, UK.
Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, UK.
Department of Respiratory Medicine, University College London, London, UK.
National Heart and Lung Institute, Imperial College London, London, UK.
Department of Interstitial Lung Disease, Royal Brompton and Harefield Hospital, Guys and St Thomas' NHS Foundation Trust, London, UK.
Department of Health Sciences, University of Leicester, Leicester, UK.
Respiratory Medicine, St George's Hospital NHS Foundation Trust, London, UK.
Roslin Institute, University of Edinburgh, Midlothian, UK.
Bristol Interstitial Lung Diseases Service, North Bristol NHS Trust, Bristol, UK.
Respiratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Academic Department of Respiratory Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK.
NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK.
School of Medicine, University of Nottingham, Nottingham, UK.
Respiratory Department, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK.
Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK.
Respiratory Medicine, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
College of Medicine and Health, University of Exeter, Exeter, UK.
Department of Oncology, University of Oxford, Oxford, UK.
Department of Molecular and Cell Biology, University of Leicester, Leicester, UK.
Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, UK.
Wythenshaw Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Southampton NIHR Biomedical Research Centre, University Hospital Southampton, Southampton, UK.
School of Life & Medical Sciences, UCL, London, UK.
UCL Respiratory, UCL, London, UK.
Head of Research and Innovation Advocacy, Asthma UK, London, UK.
Child Health, University of Liverpool, Liverpool, UK.
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Respiratory Medicine, Perth Royal Infirmary, NHS Tayside, Perth, UK.
School of Medicine, University of Dundee, Dundee, UK.
Respiratory Medicine, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
Division of Diabetes, Endocrinology & Gastroenterology, The University of Manchester, Manchester, UK.
Birmingham Acute Care Research Group, University of Birmingham, Birmingham, UK.
Acute and Respiratory Medicine, University Hospitals Birmingham Foundation Trust, Birmingham, uk.
Institute of Infection Veterinary and Ecological Science, University of Liverpool, Liverpool, UK.
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine Oncology, Oxford, UK.
Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford, UK.
Centre for Medical Imaging and Computing, University College London, London, UK.
National Heart and Lung Institute, Imperial College London, London, UK

Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD). Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment. Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals. Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.

中文翻译：

了解 COVID-19 后间质性肺疾病的负担：英国间质性肺疾病 - 长新冠病毒研究 (UKILD-长新冠病毒)

简介 COVID-19 大流行已导致全球出现超过 1 亿例病例。英国已有超过 400 万例病例、40 万人入院、10 万人死亡。许多 COVID-19 患者无论是否住院，都会遭受长期症状，主要是呼吸困难和疲劳。早期数据表明，COVID-19 潜在的严重长期后果是发展为与 COVID-19 相关的长期间质性肺疾病 (LC-ILD)。方法和分析英国间质性肺疾病联盟 (UKILD) 将对疑似 ILD 的 COVID-19 患者进行纵向观察研究。主要目标是确定感染后 12 个月的 ILD 患病率以及临床严重感染是否与 ILD 严重程度相关。次要目标将确定决定 ILD 恢复或进展轨迹的临床、遗传、表观遗传和生化因素。数据将通过与住院后新冠病毒平台研究和社区研究的联系来获取。其他子研究将进行深度表型分析。肺泡功能障碍的氙 MRI 检查子研究将进行纵向氙气肺泡气体转移和质子灌注 MRI。POST COVID-19 间质性肺疾病子研究将进行临床指示的支气管肺泡灌洗和匹配的全血采样。评估包括探索性单细胞 RNA 和肺微生物组学分析、基因表达和表观遗传评估。伦理与传播所有贡献研究均已获得适当的伦理批准。这项研究的结果将通过同行评审期刊传播。结论这项研究将确保确定 LC-ILD 的范围和后果，并制定减缓 LC-ILD 进展的策略。

更新日期：2021-09-24

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>